Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-09-20
2004-03-09
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C435S184000, C548S204000, C548S205000
Reexamination Certificate
active
06703403
ABSTRACT:
TECHNICAL FIELD
The present invention relates to a novel composition and a method for improving the pharmacokinetics of drugs which are metabolized by cytochrome P450 monooxygenase. In addition, the present invention relates to a novel composition and a method for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease and a composition and a method for inhibiting a retroviral infection, in particular an HIV infection.
BACKGROUND OF THE INVENTION
Infection by the retrovirus known as human immumodeficiency virus (HIV) continues to be a serious human health problem. Methods for treating HIV infections include administering agents which inhibit the activity of viral enzymes which are essential to the life cycle of the virus.
The genomes of retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the pol and gag gene products. See Wellink, Arch. Virol. 98 1 (1988). Retroviral proteases most commonly process the gag precursor into core proteins, and also process the pol precursor into reverse transcriptase and retroviral protease. Retroviral proteases are known to be sequence specific. See Pearl, Nature 328 482 (1987).
The correct processing of the precursor polyproteins by the retroviral protease is necessary for the assembly of infectious virions. It has been shown that in vitro mutagenesis that produces protease-defective virus leads to the production of immature core forms which lack infectivity. See Crawford, J. Virol. 53 899 (1985); Katoh, et al., Virology 145 280 (1985). Therefore, retroviral protease inhibition provides an attractive target for antiviral therapy. See Mitsuya, Nature 325 775 (1987).
It has recently been disclosed that the HIV protease inhibitor ritonavir (also known as ABT-538) is effective in humans for inhibiting an HIV infection.
It has also been discovered that ritonavir is an inhibitor of the metabolic enzyme cytochrome P450 monooxygenase.
Some drugs and, in particular, some HIV protease inhibitors are metabolized by cytochrome P450 monooxygenase, leading to unfavorable pharmacokinetics and the need for more frequent and higher doses than are most desirable. Administration of such drugs with an agent that inhibits metabolism by cytochrome P450 monooxygenase will improve the pharmacokinetics (i.e., increase half-life, increase the time to peak plasma concentration, increase blood levels) of the drug.
It has been discovered that coadministration of ritonavir with a drug which is metabolized by cytochrome P450 monooxygenase, especially the P450 3A4 isozyme, causes an improvement in the pharmacokinetics of such a drug.
In particular, it has been discovered that coadministration of ritonavir with an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase causes an unexpected improvement in the pharmacokinetics of such an HIV protease inhibitor.
REFERENCES:
patent: 5142056 (1992-08-01), Kempf et al.
patent: 5196438 (1993-03-01), Martin et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5484801 (1996-01-01), Al-Razzak et al.
patent: 5484926 (1996-01-01), Dressman et al.
patent: 5567823 (1996-10-01), Tien et al.
patent: 5674882 (1997-10-01), Kempf et al.
patent: 5886036 (1999-03-01), Kempf et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6054490 (2000-04-01), Sime et al.
patent: 0532466 (1993-03-01), None
patent: 0560268 (1993-09-01), None
patent: 0574135 (1993-12-01), None
patent: 0580402 (1994-01-01), None
patent: 0618222 (1994-10-01), None
patent: 0541168 (1995-05-01), None
patent: 0687675 (1995-12-01), None
patent: 0691345 (1996-10-01), None
patent: 9208701 (1992-05-01), None
patent: 9307128 (1993-04-01), None
patent: 9323368 (1993-11-01), None
patent: 9405639 (1994-03-01), None
patent: 9414436 (1994-07-01), None
patent: 9418188 (1994-08-01), None
patent: 9506030 (1995-03-01), None
patent: 9507696 (1995-03-01), None
patent: 9509614 (1995-04-01), None
patent: 9509843 (1995-04-01), None
patent: 9510281 (1995-04-01), None
patent: 9511224 (1995-04-01), None
patent: 9511992 (1995-05-01), None
patent: 9533464 (1995-12-01), None
patent: 9604913 (1996-02-01), None
J. James, AIDS Treatment News, No. 231 Sep. 29, 1995.
D. Kempf, et al., 3rdConf Retro and Opportun Infect (US) Jan. 28-Feb. 1, 1996 p. 79.
J. Partaledis, et al., Journal of Virology, Sep. 1995 p. 5228-5235—In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease.
J. Craig, et al., Int. Conf. AIDS 9 (1993) PO-A25-0602; RO-31-8959, An Inhibitor of HIV Proteinase, Acts Beneficially With Other Antiviral Agents in 2- and 3-Way Combinations in Vitro.
S. Vella, Rationale and Experience With Reverse Transcriptase Inhibitors and Protease Inhibitors, Journ Of Acquired Immune Def. Syndrome & Humane Retro. 10(Suppl. 1) S58-S61 1995.
G. Yee, et al., Lancet 345 955 (1995).
Bertz Richard J.
Kempf Dale J.
Leonard John M.
Norbeck Daniel W.
Abbott Laboratories
Crowley Steven R.
McIntosh III Traviss C.
Wilson James O.
LandOfFree
Method for improving pharmacokinetics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for improving pharmacokinetics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for improving pharmacokinetics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3189273